MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sammaster who wrote (1634)	12/19/2005 12:54:43 AM
From: tuck	Read Replies (1) of 1826

This is either kind of embarrassing to me or a testament to Erik's intellectual capacity: I could have written something like what Erik wrote if I had listened to the presentation TWICE -- and English is my first language! Thanks, Erik, for the clarification. >>2007 will bring generic zofran and much greater cost differential so hospitals will be quick to drop aloxi since zofran is not a "bad" drug.. hospitals are governed by profit margins if one drug is not clearly much more superior to another<< How true is this, really? Don't hospitals have the same reimbursement set up? Am I displaying even more ignorance here? I can certainly see insurers being interested in generic Zofran, if the cost/benefit of it is worth it (i.e. if there are more adverse outcomes, longer hospital stays, what have you -- from Zofran but the cost of them doesn't wipe out the difference in price between it and Aloxi -- and that's assuming they're utterly cold-blooded), but the hospitals? Wouldn't your scenario only be true for the uninsured? Thanks for any help on my edification in this matter. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next